Endometrial Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Cancer Type (Endometrial Carcinoma, Uterine Sarcomas), By Therapy (Immunotherapy, Radiation Therapy, Chemotherapy, Other Types of Therapies), By Diagnosis Method (Biopsy, Pelvic Ultrasound, Hysteroscopy, CT scan, Other Diagnosis Methods), By End Use (Hospitals, Imaging Centers, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 30.90 Billion
CAGR (2026-2031)	6.19%
Fastest Growing Segment	Immunotherapy
Largest Market	North America
Market Size (2031)	USD 44.31 Billion

Market Overview

The Global Endometrial Cancer Market will grow from USD 30.90 Billion in 2025 to USD 44.31 Billion by 2031 at a 6.19% CAGR. The Global Endometrial Cancer Market encompasses a range of diagnostic technologies and therapeutic interventions, such as surgery, chemotherapy, radiation, and pharmacotherapies, intended to manage malignancies originating in the uterine lining. The primary drivers fueling market expansion include the rising global prevalence of obesity and metabolic syndromes, which are significant risk factors, alongside an aging female population susceptible to oncological conditions. Additionally, the introduction of targeted drug therapies and immunotherapies has broadened the treatment landscape for patients with recurrent or metastatic disease. According to the American Cancer Society, in 2024, an estimated 67,880 new cases of uterine cancer were projected to be diagnosed in the United States, highlighting the growing clinical demand for effective management solutions.

However, the market confronts a substantial obstacle regarding the high cost associated with novel biologic agents and immune checkpoint inhibitors. These elevated expenses often lead to rigorous reimbursement scrutiny and limited accessibility in regions with cost-sensitive healthcare systems. Consequently, financial barriers and disparate access to care serve as significant challenges that may restrict the widespread adoption of approved therapies and impede overall market penetration in developing economic regions.

Key Market Drivers

The rising global incidence of endometrial cancer, significantly exacerbated by the increasing prevalence of obesity and metabolic syndromes, acts as a primary catalyst for market growth. As excess adipose tissue increases estrogen exposure, the risk of developing malignant uterine conditions escalates, particularly in developed nations with shifting lifestyle patterns. This upward trend in disease burden is not only limited to case numbers but also reflects in severity outcomes, necessitating urgent clinical attention. According to the American Cancer Society, January 2024, in the 'Cancer Statistics, 2024' report, mortality rates for uterine corpus cancer continue to increase by 2% per year, marking it as one of the few oncological indications with rising death rates. This alarming trajectory drives the demand for accelerated development of diagnostic screening and robust therapeutic interventions to manage the expanding patient population effectively.

Concurrently, advancements in immunotherapy and targeted therapeutics are reshaping treatment paradigms, moving beyond traditional chemotherapy to offer improved survival outcomes for advanced stages. Recent regulatory milestones have expanded the applicability of immune checkpoint inhibitors to broader patient subgroups, including those previously limited to palliative care options. For instance, according to GSK, August 2024, in a press release regarding the RUBY phase III trial, the combination of dostarlimab and chemotherapy demonstrated a 31% reduction in the risk of death compared to chemotherapy alone in the overall patient population. This therapeutic evolution is crucial given the molecular diversity of the malignancy; according to AstraZeneca, June 2024, in an announcement regarding the DUO-E trial results, approximately 20% to 30% of individuals with endometrial cancer have mismatch repair deficient (dMMR) disease, highlighting the critical market shift towards biomarker-driven precision medicine.

Download Free Sample Report

Key Market Challenges

The high acquisition cost associated with novel biologic agents and immune checkpoint inhibitors acts as a substantial restraint on the expansion of the endometrial cancer market. These elevated expenses necessitate rigorous scrutiny from insurance providers and government healthcare programs, often resulting in delayed or denied reimbursement coverage. Consequently, healthcare systems in cost-sensitive regions frequently restrict the inclusion of these premium therapies in their standard formularies, thereby limiting the addressable patient population for pharmaceutical developers.

This economic pressure directly hampers market growth by slowing the uptake of approved drugs in developing markets and underfunded public health sectors. The inability to secure consistent reimbursement creates a disparity in care delivery, leaving a significant portion of the patient base reliant on older, less expensive treatment modalities. According to the American Cancer Society, in 2024, approximately 13,250 deaths from cancers of the uterine body were projected to occur in the United States. This mortality figure underscores the critical gap where financial inaccessibility to advanced therapeutic interventions limits the potential reduction in disease burden and constrains overall market revenue generation.

Key Market Trends

The emergence of Antibody-Drug Conjugates (ADCs) for targeted delivery represents a pivotal shift in the therapeutic landscape, providing a mechanism to transport potent cytotoxic payloads directly to tumor-associated antigens such as TROP2 and HER2. This modality addresses a critical unmet need for patients who progress on platinum-based chemotherapy and immunotherapy, offering a precision alternative to standard systemic toxicities. By leveraging specific biomarker expression, ADCs enable effective intervention in advanced disease settings where treatment options were previously limited. According to The ASCO Post, August 2024, in the 'Sacituzumab Govitecan in Advanced Endometrial Cancer' report, the phase II TROPiCS-03 trial demonstrated that sacituzumab govitecan achieved an objective response rate of 22% in patients with advanced endometrial cancer who had received prior therapies.

Simultaneously, the utilization of artificial intelligence in pathology is revolutionizing diagnostic accuracy by identifying high-risk tumor features that often escape conventional histological assessment. These AI-driven tools facilitate the transition toward precise molecular classification, allowing clinicians to stratify patients based on recurrence risk more effectively than improved staging systems alone. This technological integration is particularly vital for distinguishing aggressive subtypes within morphologically similar tumor groups, thereby optimizing personalized care plans. According to the University of British Columbia, June 2024, in the 'Scientists discover high-risk form of endometrial cancer' article, researchers utilized a new AI model to pinpoint a distinct high-risk subset of endometrial cancer that would otherwise go unrecognized by traditional pathology and molecular diagnostics.

Segmental Insights

Immunotherapy stands as the fastest-growing segment in the Global Endometrial Cancer Market, driven by the introduction of immune checkpoint inhibitors that address significant unmet medical needs. The expansion is primarily supported by the U.S. Food and Drug Administration granting approvals for therapies targeting specific biomarkers, such as mismatch repair deficiency, in patients with advanced or recurrent disease. These regulatory milestones have validated immunotherapy as a potent alternative to standard platinum-based chemotherapy. As a result, the superior clinical efficacy of these drugs in second-line treatment settings continues to fuel their widespread adoption and subsequent market growth.

Regional Insights

North America maintains a dominant position in the global endometrial cancer market, primarily driven by the high incidence of the condition within the United States. The region benefits from established healthcare infrastructure and widespread accessibility to effective diagnostic methods. Market growth is further supported by the proactive role of the US Food and Drug Administration in accelerating therapeutic approvals. Additionally, the presence of major pharmaceutical manufacturers and favorable reimbursement policies for cancer treatments contribute significantly to the continuous expansion of the sector in this geography.

Recent Developments

• In August 2025, Genmab A/S announced that the U.S. FDA granted Breakthrough Therapy Designation to rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα). This designation was assigned for the treatment of adult patients with recurrent or progressive endometrial cancer who have previously received platinum-based chemotherapy and an immune checkpoint inhibitor. The regulatory decision was supported by preliminary data from the Phase 1/2 RAINFOL-01 clinical trial, which evaluated the safety and anti-tumor activity of the compound. This development highlights the growing focus on antibody-drug conjugates as a potential therapeutic class within the global endometrial cancer market.
• In August 2024, GSK received expanded approval from the U.S. FDA for Jemperli (dostarlimab) in combination with chemotherapy for the treatment of adult patients with primary advanced or recurrent endometrial cancer. This decision broadened the indication to include all patients regardless of their mismatch repair (MMR) status, making it the first immuno-oncology therapy approved in the frontline setting for the overall patient population. The approval was based on the results from Part 1 of the Phase 3 RUBY trial, which showed a clinically meaningful survival benefit in the overall population, including those with mismatch repair proficient (MMRp) or microsatellite stable (MSS) tumors, a group that historically had limited treatment options.
• In August 2024, AstraZeneca secured approval from the European Commission for Imfinzi (durvalumab) and Lynparza (olaparib) as a treatment for certain patients with endometrial cancer. The Commission authorized the use of Imfinzi in combination with chemotherapy as a first-line treatment followed by Imfinzi plus Lynparza for patients with mismatch repair proficient (pMMR) advanced or recurrent endometrial cancer. Additionally, the approval included Imfinzi plus chemotherapy followed by Imfinzi alone for patients with mismatch repair deficient (dMMR) disease. This regulatory action, based on the DUO-E Phase 3 trial results, established this regimen as the first combination of an immunotherapy and a PARP inhibitor approved for endometrial cancer in the European Union.
• In June 2024, Merck announced that the U.S. Food and Drug Administration (FDA) approved its anti-PD-1 therapy, Keytruda, in combination with carboplatin and paclitaxel, followed by Keytruda as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. This regulatory milestone marked the third indication for Keytruda in endometrial carcinoma and the first for this specific combination in the frontline setting regardless of mismatch repair status. The approval was supported by data from the Phase 3 NRG-GY018 trial, which demonstrated that the immunotherapy combination statistically significantly improved progression-free survival compared to chemotherapy alone in this patient population.

Key Market Players

• Elekta
• Karyopharm Therapeutics Inc.
• Eisai Co., Ltd
• GSK plc
• Siemens Healthineers AG
• Johnson & Johnson
• Boston Scientific Corporation
• Pfizer Inc.
• Bayer AG
• Bristol-Myers Squibb Company

By Cancer Type	By Therapy	By Diagnosis Method	By End Use	By Region
Endometrial Carcinoma Uterine Sarcomas	Immunotherapy Radiation Therapy Chemotherapy Other Types of Therapies	Biopsy Pelvic Ultrasound Hysteroscopy CT scan Other Diagnosis Methods	Hospitals Imaging Centers Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Endometrial Cancer Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Endometrial Cancer Market, By Cancer Type:

• Endometrial Carcinoma
• Uterine Sarcomas

• Endometrial Cancer Market, By Therapy:

• Immunotherapy
• Radiation Therapy
• Chemotherapy
• Other Types of Therapies

• Endometrial Cancer Market, By Diagnosis Method:

• Biopsy
• Pelvic Ultrasound
• Hysteroscopy
• CT scan
• Other Diagnosis Methods

• Endometrial Cancer Market, By End Use:

• Hospitals
• Imaging Centers
• Others

• Endometrial Cancer Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE